PepGen (NASDAQ:PEPG - Get Free Report) will likely be announcing its earnings results before the market opens on Wednesday, March 5th. Analysts expect the company to announce earnings of ($0.84) per share for the quarter.
PepGen (NASDAQ:PEPG - Get Free Report) last issued its earnings results on Monday, February 24th. The company reported ($0.68) earnings per share for the quarter, beating analysts' consensus estimates of ($0.81) by $0.13. On average, analysts expect PepGen to post $-3 EPS for the current fiscal year and $-2 EPS for the next fiscal year.
PepGen Stock Up 29.6 %
Shares of PEPG stock traded up $0.72 during trading hours on Friday, reaching $3.15. The company's stock had a trading volume of 8,938,895 shares, compared to its average volume of 4,157,341. PepGen has a fifty-two week low of $1.16 and a fifty-two week high of $19.30. The company has a market capitalization of $102.68 million, a price-to-earnings ratio of -1.06 and a beta of 1.53. The firm's 50 day simple moving average is $2.37 and its 200-day simple moving average is $5.69.
Analyst Ratings Changes
Several equities research analysts recently weighed in on PEPG shares. Bank of America downgraded PepGen from a "neutral" rating to an "underperform" rating and set a $3.00 price objective on the stock. in a report on Monday, December 16th. HC Wainwright reissued a "buy" rating and set a $16.00 price objective on shares of PepGen in a report on Monday, February 24th. Finally, Wedbush cut their price objective on PepGen from $19.00 to $12.00 and set an "outperform" rating on the stock in a report on Friday, November 8th.
Get Our Latest Research Report on PepGen
PepGen Company Profile
(
Get Free Report)
PepGen Inc, a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients.
Recommended Stories
Before you consider PepGen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and PepGen wasn't on the list.
While PepGen currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
